These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22101862)

  • 1. Reactive perforating collagenosis during erlotinib therapy.
    Suzuki Y; Yamamoto T
    Acta Derm Venereol; 2012 Mar; 92(2):216-7. PubMed ID: 22101862
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease.
    Calista D; Morri M
    Eur J Dermatol; 2008; 18(1):84-5. PubMed ID: 18086600
    [No Abstract]   [Full Text] [Related]  

  • 3. A giant variant of acquired reactive perforating collagenosis associated with hydronephrosis: successful treatment with allopurinol.
    Gnanaraj P; Venugopal V; Sangitha C; Rajagopalan V; Pandurangan CN
    Int J Dermatol; 2009 Feb; 48(2):204-6. PubMed ID: 19200207
    [No Abstract]   [Full Text] [Related]  

  • 4. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis.
    Lübbe J; Sorg O; Malé PJ; Saurat JH; Masouyé I
    Dermatology; 2008; 216(3):239-42. PubMed ID: 18182818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired reactive perforating collagenosis: four patients with a giant variant treated with allopurinol.
    Hoque SR; Ameen M; Holden CA
    Br J Dermatol; 2006 Apr; 154(4):759-62. PubMed ID: 16536825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Painful pustular eruption in the groin and the scrotum induced by erlotinib.
    Cholongitas E; Kokolakis GP; Ioannidou D
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):507-8. PubMed ID: 18363921
    [No Abstract]   [Full Text] [Related]  

  • 7. Reactive perforating collagenosis associated with diabetes mellitus.
    Poliak SC; Lebwohl MG; Parris A; Prioleau PG
    N Engl J Med; 1982 Jan; 306(2):81-4. PubMed ID: 7053490
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 9. Rosaceiform eruption induced by erlotinib.
    Patrizi A; Bianchi F; Neri I
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S43-5. PubMed ID: 18837734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired reactive perforating collagenosis.
    Basak PY; Turkmen C
    Eur J Dermatol; 2001; 11(5):466-8. PubMed ID: 11525959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purpuric drug eruption and alopecia induced by erlotinib.
    Nakamura-Wakatsuki T; Yamamoto T
    Dermatol Online J; 2012 May; 18(5):16. PubMed ID: 22630586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type.
    Lederhandler M; Beasley JM; Brinster NK; Nagler AR
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
    Campbell TM; Brown CW
    J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib-induced generalized eczema craquelé and follicular rash sparing the previous radiation field.
    Chiu HY; Cheng YP; Jee SH; Tsai TF
    Clin Exp Dermatol; 2012 Dec; 37(8):922-4. PubMed ID: 22731795
    [No Abstract]   [Full Text] [Related]  

  • 15. Reactive perforating collagenosis and acquired perforating dermatosis: presentation of two cases.
    Kyriaki A; Ephtichia Z; Anna L; Panagiotis D
    J Dermatol; 1997 Mar; 24(3):170-3. PubMed ID: 9114614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gangrenous staphylococcal infections localized on the lesions of acquired reactive perforating collagenosis.
    Kashino K; Senoo A; Yamasaki O; Iwatsuki K
    J Dermatol; 2008 Sep; 35(9):594-7. PubMed ID: 18837706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib-induced dermatologic side-effects.
    Bovenschen HJ; Alkemade JA
    Int J Dermatol; 2009 Mar; 48(3):326-8. PubMed ID: 19261029
    [No Abstract]   [Full Text] [Related]  

  • 18. Erlotinib-induced reactive perforating collagenosis in a case of lung adenocarcinoma.
    Jiang X; Song TT; Hao F
    Indian J Dermatol Venereol Leprol; 2021 [SEASON]; 87(4):548-551. PubMed ID: 34219432
    [No Abstract]   [Full Text] [Related]  

  • 19. Erlotinib-associated skin reactions - case report and proposal for classification.
    Zoller A; Schäd SG; Gross GE
    Br J Dermatol; 2006 Dec; 155(6):1293-5. PubMed ID: 17107405
    [No Abstract]   [Full Text] [Related]  

  • 20. Acquired reactive perforating collagenosis.
    Cohen RW; Auerbach R
    J Am Acad Dermatol; 1989 Feb; 20(2 Pt 1):287-9. PubMed ID: 2915063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.